Floatz logo

5-((R)-SEC-BUTYLAMINO)-N1-((1R,3S,5S)-8-(5-(CYCLOPROPANECARBONYL)PYRIDIN-2-YL)-8-AZABICYCLO(3.2.1)OCTAN-3-YL)-2-METHYLTEREPHTHALAMIDE

Metastatic Pancreatic Adenocarcinoma

Emory UniversitySmall moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

190 Active assets in the Metastatic Pancreatic Adenocarcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Docetaxel
Bristol-Myers Squibb
Phase 2BBB
Irinotecan
Jonsson Comprehensive Cancer Center
Phase 3BB
Eloxatin
Jonsson Comprehensive Cancer Center
Phase 4BB
Irinotecan
Ipsen
Phase 3BB

View all 50 →

Same molecule, other indications

5-((R)-SEC-BUTYLAMINO)-N1-((1R,3S,5S)-8-(5-(CYCLOPROPANECARBONYL)PYRIDIN-2-YL)-8-AZABICYCLO(3.2.1)OCTAN-3-YL)-2-METHYLTEREPHTHALAMIDE is also rated in:

colorectal carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
exocrine pancreatic carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
colorectal cancerDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →